Jean-François Thériault

TL;DR: The dual functional 17β-HSD7 is proposed as a novel target for estrogen-dependent breast cancer by regulating the balance of E2 and DHT by suppressing cell growth and triggering apoptosis and auto-downregulation feedback of the enzyme.

TL;DR: The central role of 17β-HSD7 in sex-hormone conversion and regulation is demonstrated, supporting it as a novel target for estrogen-dependent (ER+) BC and demonstrating that fundamental enzymological mechanisms are relevant in living cells.

TL;DR: It is demonstrated for the first time that down-regulation of 3α-HSD3 decreases MCF7 breast cancer cell growth, and structural clues for 5α-DHT reverse binding in the enzyme with the generation of different products are provided.

TL;DR: The chemical synthesis of four stereoisomers of 16β-(m-carbamoylbenzyl)-estradiol, a potent reversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1, and two intermediates was performed, and no compound showed an androgenic activity.

TL;DR: The kinetic and binding results strongly support that the inhibition of 17β-HSD7 constitutes the basis of breast cancer cell proliferation decreasing that led to the shrinkage of xenograft ER + breast tumor mice model.